NCT01148498已完成2 期
Plasma Amyloid Beta Species After a Single Solanezumab Infusion in Nondemented Individuals and Those With Mild Dementia of the Alzheimer's Type
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 55
- 试验地点
- 1
- 主要终点
- Mean change from baseline up to 112 days post drug administration in plasma levels of Aβ fragment-2 in (Group 1) and (Group 3)
研究概览
简要总结
The purpose of this trial is to compare the average change in the amount of amyloid beta species in blood after an infusion of solanezumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Individuals in Groups 1, 2, and 3, described below, will be participants in the longitudinal studies of memory and aging at the Washington University Alzheimer's Disease Research Center (WU-ADRC). These participants must have results from apolipoprotein E (ApoE) genotyping from the WU-ADRC. At the beginning of the study they must be between 45 and 90 years of age and if a female of childbearing potential, not be breastfeeding, test negative for pregnancy, and be using a medically accepted form of birth control at the time of the infusion and for 6 months afterward. Subjects must also meet the criteria below for each study group
- •Group 1, Mild dementia of Alzheimer's type (DAT):
- •Have mild DAT, as determined by Clinical Dementia Rating (CDR) of 0.5 or 1
- •Have florbetapir PET imaging findings consistent with underlying AD pathology.
- •Group 2, Older Adult Controls with Possible AD Pathology:
- •Have no cognitive impairment as indicated by a CDR rating of
- •Have possible AD pathology, as determined by florbetapir PET imaging.
- •Group 3, Older Adult Controls with No Evidence of AD Pathology:
- •Have no cognitive impairment as indicated by a CDR rating of
- •Have no evidence of AD pathology as determined by florbetapir PET imaging.
- •Individuals recruited into Group 4 will not be participants in the longitudinal studies of memory and aging at WU-ADRC. To be included in Group 4, individuals must meet these criteria:
- •Are at least 18 years and <35 years of age at the beginning of the study and if a female of childbearing potential, is not breastfeeding, tests negative for pregnancy and is using highly effective contraception at the time of the solanezumab infusion and for 6 months following infusion
- •Have a Folstein Mini-Mental State Examination (MMSE) score of 29 to 30 at the beginning of the study
排除标准
- •Have previously completed or withdrawn from this study or any other study investigating solanezumab
- •Does not have good venous access, such that intravenous drug delivery or multiple blood draws would be precluded
- •Has allergies to humanized monoclonal antibodies
- •Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis)
- •Has a history of chronic alcohol or drug abuse/dependence
- •Is clinically judged by the investigator to be at serious risk for suicide
- •Has a recent (within 6 months before screening) or current laboratory result (if available) indicating a clinically significant laboratory abnormality
- •Has Electrocardiogram (ECG) abnormalities obtained at screening that, in the opinion of the investigator, are clinically significant with regard to the subject's participation in the study. Bazett's corrected QT [QTcB] interval must be evaluated and must not exceed >458 msec in males or >474 msec in females
- •At screening, has alanine transaminase (ALT/SGPT) values greater than or equal to 2 times the upper limit of normal (ULN) of the performing laboratory, aspartate transaminase (AST/SGOT) values greater than or equal to 3 times the ULN, or total bilirubin values greater than or equal to 2 times the ULN
- •Has had IgG therapy (sometimes called gamma globulin therapy) within the last year or previous participation in any other study investigating active immunization against Aβ
- •Requires treatment with other monoclonal antibodies
研究组 & 干预措施
Group 1
Experimental
Older adults with mild Dementia Alzheimer's Type (DAT)
干预措施: solanezumab (Drug)
Group 2
Experimental
Older adult controls with possible Alzheimer's Disease Pathology
干预措施: solanezumab (Drug)
Group 3
Experimental
Older adult controls with no evidence of Alzheimer's Disease
干预措施: solanezumab (Drug)
Group 4
Experimental
Younger subjects who are assumed to have no cognitive impairment
干预措施: solanezumab (Drug)
结局指标
主要结局
Mean change from baseline up to 112 days post drug administration in plasma levels of Aβ fragment-2 in (Group 1) and (Group 3)
时间窗: Baseline up to 112 days post drug administration
次要结局
- Mean change in plasma levels of Aβ1-42 after solanezumab infusion(Baseline (pre-dose); 30 minutes; 24 hours; 7, 28, 56 and 112 days post-dose)
- Mean change in plasma levels of Aβ1-40 species after solanezumab infusion(Baseline (pre-dose); 30 minutes; 24 hours; 7, 28, 56 and 112 days post-dose)
- Mean change in plasma levels of modified Aβ species after solanezumab infusion(Baseline (pre-dose); 30 minutes; 24 hours; 7, 28, 56 and 112 days post-dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Study to Evaluate Amyloid in Blood and Imaging Related to DementiaAlzheimer DiseaseAlzheimer DementiaNCT03899844Washington University School of Medicine1,122
已完成
不适用
Sleep Quality and Amyloid-Beta KineticsAmyloid-betaNCT03077620Washington University School of Medicine48
终止
1 期
Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's DiseaseAlzheimer DiseaseNCT00739037Wyeth is now a wholly owned subsidiary of Pfizer10
已完成
不适用
Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep InductionAmyloid-betaNCT02063217Washington University School of Medicine36
已完成
不适用
Brain Energy for Amyloid Transformation in Alzheimer's Disease StudyMild Cognitive ImpairmentAlzheimer DiseaseNCT03472664Wake Forest University Health Sciences84